



## **Sosei Announces Progression of SD118 Towards Phase 1 Studies**

**Tokyo, Japan – 21st February 2007:** Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), a biopharmaceutical company, today announces that its collaborative project SD118, which is under development for the treatment of neuropathic pain, has successfully completed regulatory pre-clinical studies and will now be progressed into Phase 1 clinical trials.

SD118 is being jointly developed with NeuroDiscovery Ltd (ASX Code: NDL) and its wholly owned subsidiary NeuroSolutions Ltd under a Collaboration Agreement concluded in June 2006. SD118 was previously under investigation in Japan for a different indication and now, following re-profiling, has demonstrated its potential as a new oral neuropathic pain therapy.

Sosei will shortly make a Clinical Trial Application in the UK to facilitate the Phase 1 trials commencement.

Mr Shinichi Tamura, President & CEO of Sosei, said: "I am delighted that we have been able to announce the completion of the pre-clinical work for SD118, further validating Sosei's expertise in successfully re-profiling compounds for new indications and its ability to provide potential compounds to replenish its pipeline."

### **Sosei Group Corporation**

Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan  
Hiroki MAEKAWA, Representative Executive Officer,  
E-mail: [hmaekawa@sosei.com](mailto:hmaekawa@sosei.com) Tel: **+81-3-5210-3399** Fax: +81-3-5210-3291

### **Sosei R&D Ltd..**

Chesterford Research Park, Saffron Walden, CB10 1XL England  
John DAFFURN, SVP Corporate Development,  
E-mail: [daffurnj@sosei.com](mailto:daffurnj@sosei.com) Tel: **+44 (0)1799 532 3500** Fax: +44 (0)1799 532 3501

### **Financial Dynamics**

Julia Phillips

**Tel: + 44 (0)207 831 3113**

### **The Trout Group**

Thomas Fechtner

**Tel: +1 646-378-2915**

**Tel: +1 646-378-2931**

### **NeuroDiscovery Ltd**

David McAuliffe

Level 11 225 St Georges Tce, Perth, WA, Australia

E-mail: [macdavid@inet.net.au](mailto:macdavid@inet.net.au)

**Tel: +61 89 226 4033**

## **Notes for Editors:**

### **About Sosei**

Sosei Group Corporation is a leading international biopharmaceutical company with significant expertise in product discovery and development. It has established a reduced risk business model primarily upon identifying new uses for established drugs and exploiting its unique position within Japanese, European and North American pharmaceutical markets by acquiring compounds from, and bringing compounds into, Japan.

For further information about Sosei, please visit [www.osei.com](http://www.osei.com)

### **About NeuroDiscovery**

NeuroDiscovery Ltd is an ASX listed neurology research and development company which owns 100% of NeuroSolutions Ltd (ASX Code: NDL). For further information visit [www.neurodiscoveryltd.com](http://www.neurodiscoveryltd.com).

### **About NeuroSolutions**

NeuroSolutions Limited is a profitable service company, applying its broad expertise and drug discovery platforms to become a leading provider of specialised electrophysiological assays to the biopharmaceutical industry. Electrophysiology is a specialised technique which is used to record electrical activity in membranes, cells, tissues or in vivo. NeuroSolutions current clients include many other established pharmaceutical and biotechnology companies.

In parallel to running its service business, the Company is also exploiting its in house technologies and expertise for its own internal R&D

For further information visit [www.nsolns.com](http://www.nsolns.com).

### **About Neuropathic Pain**

Neuropathic pain is associated with peripheral or central nervous system injury. It is often described as “burning” or “shooting” in nature and can be continuous or paroxysmal. It is estimated that up to 5% of the general population of the USA, Europe and Japan are affected by neuropathic conditions including diabetic neuropathic pain and post-herpetic neuralgia.

The disease is predominantly treated at present with a variety of anticonvulsant, antidepressant and analgesic drugs but many patients fail to respond adequately to these agents. Consequently neuropathic pain is recognised as an area of significant unmet medical need. The global market value for neuropathic pain treatments is currently estimated at \$2.1Bn and is predicted to rise to \$5.5Bn by 2015.